Platinum(IV)-gold(I) agents with promising anticancer activity: Selected studies in 2D and 3D triple-negative breast cancer models (Contel et al. @ContelLab @javoed_@naznayeem @AfrujaAhad@jpcer0n@IgnacioELeon@CUNY) https://t.co/Q9u2n4nq5E
Last Invited Talk of the morning deals with a very interesting question: To patent or not to patent? That is the question for computational chemist!! We are thrilled to have to #theobio2023 José Pedro Cerón Carrasco from Universidad Politécnica de Cartagena🔝🔝
Invited as Speaker in that event by the @RoySocChem -> Ultra-large Chemical Libraries for Drug Discovery. See you in 10 days London! #compchem@cudsanjavier @UPCTnoticias
Pick of the Week, out #OpenAccess in @ChemMedChem by @jpcer0n at @UPCTnoticias:
When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends💻💊
https://t.co/p5EhD0n1F5
An in-depth look into the limitations of virtual screening, exemplified for SARSCoV2.
@cdsouthan @BShoichet Sorry, I missed your blog too. What a huge work! As you know, the (over)use of VS in the search of antivirals has been increasing since then.
@BShoichet Thanks for sharing! As concluded, docking is still a valuable tool, but post-refinement or experimental confirmation is a must to have a real impact. That’s the way to ‘unmask’ #falsetheoreticalfriends